Concert squares up to Pfizer in alopecia Jak bout
Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.
Zogenix gets an unwelcome distraction from Fintepla
Spending $250m on Modis gives Zogenix a new rare disease niche, but the timing and the target both look odd.
Where now for Oxurion?
The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.
Upcoming events – United seeks a Distinct hit, and Biogen nears a rare catalyst
A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.
Reata gets another shot in Friedreich’s ataxia
Reata Pharmaceuticals will soon find out if its decision to persevere with omaveloxolone despite an earlier failure has paid off.
Upcoming events – Atara and Aslan await validating results
Atara tackles multiple sclerosis’s virus hypothesis while Aslan needs to roar with crucial biliary tract cancer data.
Squelgene does a lopsided swap with Jounce
Celgene opts out of Jounce’s Icos agonist ahead of its merger with Bristol-Myers Squibb.
Upcoming events – catalysts approach for Catalyst and Oxurion
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
Neon and Neurotrope await signs of proof of concept
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.